Stockreport

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

MiNK Therapeutics, Inc.  (INKT) 
PDF NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogenei [Read more]